A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia-Reference-Cited by-同舟云学术

A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

Published:2013-05-22 Issue:1 Volume:13 Page:
ISSN:1471-244X
Container-title:BMC Psychiatry
language:en
Short-container-title:BMC Psychiatry

Author:

Adams David H,Kinon Bruce J,Baygani Simin,Millen Brian A,Velona Isabella,Kollack-Walker Sara,Walling David P

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health

Link

http://link.springer.com/content/pdf/10.1186/1471-244X-13-143.pdf

Reference12 articles.

1. Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD: Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (−)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther. 2007, 321: 308-317. 10.1124/jpet.106.110809.

2. Schoepp DD, Marek GJ: Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?. Curr Drug Targets CNS Neurol Disord. 2002, 1: 215-225. 10.2174/1568007024606177.

3. Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13: 261-276. 10.1093/schbul/13.2.261.

4. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007, 13: 1102-1107. 10.1038/nm1632.

5. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, Jackson K, Kryzhanovskaya L, Jarkova N, HBBI Study Group: A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011, 31: 349-355. 10.1097/JCP.0b013e318218dcd5.

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the Mechanism of Action of Antipsychotic Drugs Derived from Animal Models: Standard of Care versus Novel Targets;International Journal of Molecular Sciences;2023-08-03

2. The mGluR2/3 orthosteric agonist LY-404,039 reduces dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-07-06

3. Effects of the mGlu2/3 receptor agonist LY379268 on two models of disturbed auditory evoked brain oscillations in mice;Translational Psychiatry;2023-05-06

4. Metabotropic glutamate receptors in Parkinson's disease;International Review of Neurobiology;2023

5. The role of thalamic group II mGlu receptors in health and disease;Neuronal Signaling;2022-11-15